Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis - PMLiVE The phase 3 study included around 2,600 patients

#Amgen #KyowaKirin #rocatinlimab #atopicdermatitis #phase3study #ASCENDstudy #Tcellrebalancingtherapy #OX40receptor #drugsafety #efficacy #ROCKETtrial #primaryendpoint #secondaryendpoints #HORIZONtrial #IGNITEtrial #rocatinlimabmonotherapy #OX40inhibition
pmlive.com/pharma_news/...

European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU

#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...